Project factsheets

The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.

IMI1/IMI2/IHI

Status

Call

Programmes

Disease areas

Products

Tools and resources to improve drug development

Clear all filters

Displaying 26 projects/programmes

ADAPT-SMART

Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes

BD4BO

Big Data for Better Outcomes

Ongoing IMI2 Cardiovascular diseases Neurodegenerative diseases Cancer Alzheimer's disease BD4BO Patient involvement in R&D Big data and knowledge management Real-world data, evidence

BEAMER

Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare

Ongoing IMI2 Real-world data, evidence

BigData@Heart

Big data @ heart

Ongoing IMI2 Cardiovascular diseases BD4BO Big data and knowledge management Real-world data, evidence

COMBACTE-CDI

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Closed IMI2 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Clinical networks Real-world data, evidence

ConcePTION

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation

Ongoing IMI2 Tools for predicting/monitoring safety Biobanks Big data and knowledge management Real-world data, evidence Tools for pediatrics

DO->IT

Big data for better outcomes, policy innovation and healthcare system transformation

Closed IMI2 BD4BO Big data and knowledge management Real-world data, evidence

DRIVE

Development of Robust and Innovative Vaccine Effectiveness

Ongoing IMI2 Infectious diseases Vaccines Tools for predicting/monitoring efficacy Real-world data, evidence

EHDEN

European Health Data and Evidence Network

Ongoing IMI2 BD4BO Big data and knowledge management Real-world data, evidence

GETREAL

Incorporating real-life clinical data into drug development

Closed IMI1 Clinical trial design Real-world data, evidence Regulatory and HTA processes

GetReal Initiative

The GetReal Initiative

Closed IMI2 Clinical trial design Real-world data, evidence Regulatory and HTA processes

H2O

H2O Health outcomes observatory

Ongoing IMI2 Diabetes & metabolic disorders Autoimmune diseases Cancer Patient involvement in R&D Real-world data, evidence

HARMONY

Healthcare alliance for resourceful medicines offensive against neoplasms in hematology

Ongoing IMI2 Cancer BD4BO Big data and knowledge management Real-world data, evidence

HARMONY PLUS

Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS

Ongoing IMI2 Cancer BD4BO Big data and knowledge management Real-world data, evidence

IDEA-FAST

Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases

Ongoing IMI2 Neurodegenerative diseases Autoimmune diseases Clinical trial design Digital health Real-world data, evidence

MOBILISE-D

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Ongoing IMI2 Cardiovascular diseases Neurodegenerative diseases Respiratory diseases Ageing-associated diseases Tools for predicting/monitoring efficacy Digital health Real-world data, evidence

ND4BB

New Drugs for Bad Bugs

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model

NGN-PET

Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments

Closed IMI2 Pain Real-world data, evidence Drug discovery

OPTIMA

Optimal treatment for patients with solid tumours in Europe through artificial intelligence

Ongoing IMI2 Cancer Real-world data, evidence Artificial intelligence

PREFER

Patient Preferences in benefit risk assessments during the drug life cycle

Closed IMI2 Clinical trial design Patient involvement in R&D Real-world data, evidence Regulatory and HTA processes Methods for benefit/risk assessment

PREMIER

Prioritisation and risk evaluation of medicines in the environment

Ongoing IMI2 Real-world data, evidence Regulatory and HTA processes Environmental aspects

ROADMAP

Real world outcomes across the AD spectrum for better care: multi-modal data access platform

Closed IMI2 Neurodegenerative diseases Alzheimer's disease BD4BO Big data and knowledge management Real-world data, evidence

SOPHIA

Stratification of obese phenotypes to optimize future obesity therapy

Ongoing IMI2 Diabetes & metabolic disorders Patient involvement in R&D Real-world data, evidence Disease taxonomy

Trials@Home

Center of excellence – remote decentralised clinical trials

Ongoing IMI2 Clinical trial design Digital health Real-world data, evidence Regulatory and HTA processes

VITAL

Vaccines and infectious diseases in the ageing population

Ongoing IMI2 Ageing-associated diseases Infectious diseases Vaccines Tools for predicting/monitoring efficacy Real-world data, evidence

WEB-RADR 2

Closed IMI2 Tools for predicting/monitoring safety Big data and knowledge management Real-world data, evidence Regulatory and HTA processes Methods for benefit/risk assessment